Kim Helen Susan's Form 4 filing
Aktis Oncology, Inc. (AKTS) · filed Jan 12, 2026
- Accession no.
- 0001193125-26-010566
- Filed
- Jan 12, 2026
- Trade date
- Jan 12, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $15.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kim Helen SusanCIK 0001422772 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionAcquired | +4,859,370 | –F1 | – | 4,859,370 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +812,455 | $18.00 | +$14,624,190 | 5,671,825 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +134,842 | –F1 | – | 134,842 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +22,545 | $18.00 | +$405,810 | 157,387 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionDisposed | −3,900,284 | $0.00 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −108,229 | $0.00 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −959,086 | $0.00 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −26,613 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.
Referenced by the price of 2 transactions in Table I.